Skip to main content
    O

    Outset Medical Inc (OM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $3.39
    -0.34 (-9.12%)

    Market Cap: $70.39M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Outset Medical Inc (OM) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Outset Medical (OM) is expected to report earnings on Jan 11, 2027. In the quarter ended Sep 30, 2026, Outset Medical reported EPS of -$0.77, above the -$0.84 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    46%(12/26)
    Avg Surprise
    -7.34%
    Streak
    1 Q

    Upcoming Estimates

    Reports Jan 11, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.68
    Range-$0.72 - -$0.63
    6 analysts
    Revenue Consensus
    $35.43M
    Range$33.03M - $36.85M
    6 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.70
    Range-$0.82 - -$0.58
    2 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.81+13.6%
    60d ago-$0.81+13.6%
    30d ago-$0.81+13.6%
    7d ago-$0.81+13.6%
    Current-$0.70
    Revenue Consensus
    $31.10M
    Range$29.80M - $32.40M
    2 analysts

    Next Report

    OM has an expected report date of Jan 11, 2027.

    OM Earnings Call

    The latest OM earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 26 quarters below that had an estimate, OM beat 12 and missed 14. Revenue for the quarter ended Sep 30, 2026 was $33.60M, up 14.2% from $29.43M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.77-$0.84N/A+8.33%BeatN/A31 up, 0 downNov 4, 2026$33.60M
    Jun 30, 2026-$0.94-$0.88N/A-6.82%MissN/A32 up, 0 downAug 6, 2026$31.64M
    Mar 31, 2026-$0.83-$0.79-$0.83 - -$0.75-5.06%MissN/A30 up, 3 downMay 7, 2026$27.86M
    Dec 31, 2025-$0.84-$0.67-$0.85 - -$0.45-25.37%MissN/A41 up, 2 downFeb 11, 2026$28.87M
    Sep 30, 2025-$0.69-$0.65-$0.70 - -$0.62-6.15%MissN/A41 up, 3 downNov 10, 2025$29.43M
    Jun 30, 2025-$0.84-$0.98-$1.76 - -$0.64+14.29%BeatN/A43 up, 1 downAug 6, 2025$31.42M
    Mar 31, 2025-$3.24-$0.94-$1.45 - -$0.31-244.68%MissN/A44 up, 0 downMay 7, 2025$29.75M
    Dec 31, 2024-$5.55-$6.19-$6.45 - -$6.00+10.34%BeatN/A41 up, 2 downFeb 19, 2025$29.47M
    Sep 30, 2024-$5.85-$6.32-$6.90 - -$5.55+7.44%BeatN/A60 up, 0 downNov 6, 2024$28.67M
    Jun 30, 2024-$7.05-$6.79-$7.80 - -$3.75-3.83%MissN/A60 up, 0 downAug 7, 2024$27.39M
    Mar 31, 2024-$8.55-$8.23-$9.30 - -$6.60-3.89%MissN/A70 up, 0 downMay 8, 2024$28.17M
    Dec 31, 2023-$8.85-$9.22-$9.90 - -$8.25+4.01%BeatN/A60 up, 0 downFeb 21, 2024$30.51M
    Sep 30, 2023-$10.65-$10.00-$10.79 - -$8.55-6.50%MissN/A65 up, 1 downNov 7, 2023$30.36M
    Jun 30, 2023-$10.35-$10.89-$13.49 - -$10.64+4.96%BeatN/A30 up, 0 downAug 2, 2023$36.04M
    Mar 31, 2023-$10.80-$10.35-$14.09 - -$9.75-4.35%MissN/A50 up, 0 downMay 3, 2023$33.47M
    Dec 31, 2022-$10.65-$11.19-$14.84 - -$11.09+4.83%BeatN/A40 up, 0 downFeb 13, 2023$32.01M
    Sep 30, 2022-$10.50-$10.57-$13.64 - -$10.04+0.66%BeatN/A50 up, 0 downNov 8, 2022$27.76M
    Jun 30, 2022-$11.55-$8.93N/A-29.34%MissN/A51 up, 0 downAug 1, 2022$25.06M
    Mar 31, 2022-$10.05-$9.93-$11.84 - -$8.70-1.21%MissN/A52 up, 0 downMay 4, 2022$30.55M
    Dec 31, 2021-$11.55-$10.01N/A-15.38%MissN/A40 up, 0 downFeb 16, 2022$28.15M
    Sep 30, 2021-$8.85-$10.29-$12.74 - -$8.85+13.99%BeatN/A55 up, 0 downNov 3, 2021$26.32M
    Jun 30, 2021-$8.55-$10.08-$11.39 - -$9.15+15.18%BeatN/A5N/AAug 5, 2021$25.22M
    Mar 31, 2021-$8.40-$12.05-$14.24 - -$10.04+30.29%BeatN/A6N/AMay 5, 2021$22.92M
    Dec 31, 2020-$0.75-$0.66-$0.74 - -$0.60-13.64%MissN/A5N/AMar 9, 2021$17.25M
    Sep 30, 2020-$32.71-$27.37-$62.07 - -$16.64-19.51%MissN/A3N/ANov 11, 2020$13.76M
    Jun 30, 2020-$0.50-$2.58N/A+80.62%BeatN/AN/AN/ASep 16, 2020$11.74M
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$5.61, after -$27.00 the year before. It was -$33.96 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$5.61N/A
    Dec 31, 2024-$27.00N/A
    Dec 31, 2023-$40.65N/A
    Dec 31, 2022-$42.75N/A
    Dec 31, 2021-$37.35N/A
    Dec 31, 2020-$33.96N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,600 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,6246
    2026Q2Jun 30, 20263,4916
    2026Q1Mar 31, 20263,8327
    2025Q4Dec 31, 20255,1848
    2025Q3Sep 30, 20255,4218
    2025Q2Jun 30, 20255,1368
    2025Q1Mar 31, 20255,2947
    2024Q4Dec 31, 20244,8837

    2026Q3 Earnings Call

    Opening remarks

    Tina Jacobson Head of Investor Relations Good afternoon, everyone, and welcome to Outset Medical's Third Quarter 2026 Earnings Call. Today's speakers are Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer. The company issued a news release after the close of the market today, which can be found in the Investors section of outsetmedical.com. This call is being recorded and will be archived there as well. All forward-looking statements made during today's call are intended to be protected under the Private Securities Litigation Reform Act of 1995. Outset assumes no obligation to update these statements. For a list and description of the risks and uncertainties associated with the business, please refer to Outset's public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. I will now turn the call over to Leslie Trigg.

    Leslie Trigg Chair and CEO Good afternoon, everyone, and thank you for joining us. Our team executed well in the third quarter, delivering solid progress against our strategic priorities. Just as importantly, we continue doing the foundational work that is strengthening the business and aligning our teams to drive more predictable, profitable growth. I'm confident that these efforts are positioning Outset to capture the significant opportunity ahead. With that, I'll dive right into third quarter results, beginning with financial performance. Revenue of $33.6 million was up 14% year-over-year and up 6% sequentially. Each of our revenue line items contributed to growth both year-over-year and sequentially. We were particularly encouraged to see console revenue growth of 26% year-over-year, driven by new and refreshed console sales. In terms of recurring revenue, in addition to solid treatment volume, sales of our EMR offering are starting to ramp and grew 23% year-over-year. Ongoing operational initiatives improved non-GAAP gross margin, while expense discipline delivered significant operating expense leverage. Our clinical excellence team was busy again this quarter, with a full lineup of new go-live implementations completed for new customers and existing customers expanding to new locations. Among those were four of the top 10 U.S. health systems. We draw on years of valuable experience to support hospitals as they transition from outsourced to in-house, starting with a detailed project plan customized to each hospital's needs, then executing that plan through nurse training, physician education, and change management support. All of that requires well-oiled cross-functional execution, and our teams continue to deliver time and again. Beyond implementation, our clinical excellence team members collaborate with customers to maximize Tablo's system-wide benefits, helping to identify the outcomes that matter most to each organization. Tablo's unique data ecosystem, now comprising more than 10 trillion data points, enables us to track and trend key performance indicators and regularly share the insights with customers.

    Frequently Asked Questions About OM

    When is Outset Medical's next earnings date?

    Outset Medical's next earnings report is expected for Jan 11, 2027.

    Did OM beat earnings estimates last quarter?

    Yes. Outset Medical reported EPS of -$0.77 for the quarter ended Sep 30, 2026, above the -$0.84 estimate, a 8.33% surprise.

    What EPS do analysts expect from OM next quarter?

    The consensus EPS estimate for Outset Medical for the quarter ending Dec 31, 2026 is -$0.68 from 6 analysts, with estimates from -$0.72 to -$0.63.

    How often does OM beat earnings estimates?

    Outset Medical beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -31.89%.